Virpax Pharmaceuticals Inc

NASDAQ:VRPX   3:59:51 PM EDT
1.86
-0.05 (-2.62%)
Debt Financing / Related, Regulatory

Virpax Reports Successful Results Of Toxicology And Pharmacokinetic Study For Epoladerm

Published: 12/08/2021 13:11 GMT
Virpax Pharmaceuticals Inc (VRPX) - Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™.
Virpax Pharmaceuticals Inc - Single-dose Transdermal Delivery of Epoladerm Was Well-tolerated in All Minipigs.
Virpax Pharmaceuticals Inc - No Treatment-related Clinical Observations, Changes in Body Weight, Or Dermal Irritation Were Observed.
Virpax Pharmaceuticals Inc - All Epoladerm Treated Animals Had Plasma Levels of Epoladerm Confirming Transdermal Absorption.
Virpax Pharmaceuticals Inc - Data Should Strengthen Company's Ind Filing in Advance of Anticipated Start of First-in-human Clinical Trials.